VPAC2 receptor-mediated reductions in axon and dendritic outgrowth in cultured cortical neurons. Primary cortical neurons were cultured with Ro25-1553 (10 nM) or VIP (10 nM) for 3 days in vitro and double-immunostained for pNF and MAP2. (A) PG99-465 (100 nM) was treated 30 min before the treatment with Ro25-1553 or VIP. PG99-465 blocked Ro25-1553- and VIP-induced reductions in axon length (main effects: F2,215 = 8.338, P < 0.001 for Ro25-1553/VIP, F1,215 = 129.957, P < 0.0001 for PG99-465; interaction: F2,215 = 24.711, P < 0.0001), total numbers (main effects: F2,215 = 8.231, P < 0.001 for Ro25-1553/VIP, F1,215 = 127.826, P < 0.0001 for PG99-465; interaction: F2,215 = 10.525, P < 0.0001) and length (main effects: F2,215 = 3.701, P < 0.05 for Ro25-1553/VIP, F1,215 = 160.683, P < 0.0001 for PG99-465; interaction: F2,215 = 11.789, P < 0.0001) of dendrites, and dendritic complexity (main effects: F2,215 = 3.744, P < 0.05 for Ro25-1553/VIP, F1,215 = 61.073, P < 0.0001 for PG99-465; interaction: F2,215 = 3.003, P < 0.05). (B) Primary cortical neurons were prepared from VPAC2 receptor knockout (VPAC2-KO) mice and littermate wild-type mice. Ro25-1553-induced reductions in axon length (main effects: F1,156 = 12.655 P < 0.001 for treatment, F1,156 = 17.717, P < 0.0001 for genotype; interaction: F1,156 = 4.182, P < 0.05), total numbers (main effects: F1,156 = 7.274, P < 0.01 for treatment, F1,156 = 15.414, P < 0.001 for genotype; interaction: F1,156 = 15.414, P < 0.001) and length (main effects: F1,156 = 15.814, P < 0.001 for treatment, F1,156 = 14.262, P < 0.001 for genotype; interaction: F1,156 = 20.342, P < 0.0001) of dendrites, and dendritic complexity (main effects: F1,156 = 2.175, P > 0.05 for treatment, F1,156 = 19.468, P < 0.0001 for genotype; interaction: F1,156 = 5.576, P < 0.05) were abolished in cortical neurons derived from VPAC2-KO mice. Values represent mean ± SD of 40 neurons from three independent experiments. **P < 0.01 vs. control, n.s.; not significant.